Top 3 drug approvals in oncology: July 2021

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Highlights include the approval of Imfinzi® in China and Pemazyre® in the UK. Padcev® (enfortumab vedotin-ejfv) Approved: 9 July 2021 Company: Astellas Pharma US (IL, USA) Indication: Locally advanced or metastatic urothelial cancer The first key approval in July happened in the USA when the US FDA granted approval for Padcev for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy,...